Synopsis Patients with stroke/TIA not attributable to other stroke causes related to specific antithrombotic rec- ommendations (eg, AF, intracranial stenosis) should receive antithrombotic therapy for the prevention of recurrent stroke. If patients with mild stroke or high- risk TIA are evaluated early after the onset of their stroke, starting short-term DAPT followed by long-term SAPT is preferred compared with SAPT according to the reduction of risk of early recurrent stroke.384,410 Beyond 90 days after stroke, DAPT is associated with increased risk of bleeding and no benefit in long-term reduction of recurrent stroke risk.381,382 For patients not treated until later after their stroke event, use of any SAPT is indicated to reduce long-term recurrent CLINICAL STATEMENTS AND GUIDELINES Kleindorfer stroke risk. Although the optimal time to switch from DAPT to SAPT to maximize benefit and reduce risk is not entirely clear, benefit in stroke reduction with DAPT may be maximized as early as the first 21 days after the event.802 This treatment approach is summa- rized in Figure 6, with consideration of clinical event criteria, DAPT versus SAPT, and length of therapy. Tri- ple therapy with aspirin, clopidogrel, and dipyridamole and use of anticoagulation in this population are not recommended on the basis of increased bleeding risk and no benefit in stroke reduction.790,801 Recommendation-Specific Supportive Text 1. The WARSS study randomized 2206 patients with stroke not attributable to cardioembolism or high- grade carotid stenosis to adjusted-dose warfarin The pri- mary end point of 2-year recurrent ischemic stroke or death was no different between the 2 groups (17.8% warfarin versus 16% acetylsalicylic acid; HR, 1.13 [95% CI, 0.92 1.38]). 